LY6G6D and neoplasm: Overall, we concluded that LY6G6D is expressed in a significant percentage of CRC samples and could be a good target for T-cell engager, with the aim of redirecting T cells into CRC tumors, induce T cell activation and subsequent tumor cell killing.